Onkologie. 2010:4(2):120-124

Acute leukemias in children

Jan Starý
Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, Praha

Acute lymphoblastic leukemia (ALL) represents 25 % of childhood tumors being the most frequent childhood cancer. ALL is a heterogeneous

disease, biologically different from the same disease in adults. Median age at diagnosis is 5 years, the most frequent chromosomal

abnormalities are fusion gene TEL-AML1 and hyperdiploidy over 50 chromosomes. Event-free-survival is over 75 % and overall survival

85 % in children treated with combined chemotherapy intensified according to the risk group. The incidence of relapse is 15–20 % and

bone marrow transplantation is the important treatment modality in such situation. Acute myeloid leukemia (AML) represents 15 %

of childhood leukemias. The most frequent genetic subtype is monocytic leukemia with MLL rearrangement at the long arm of chromosome

11 (11q23) (20–25 % of all AML) with intermediate prognosis. Subtypes with good prognosis – acute promyelocytic leukemia

with t (15; 17), myeloid leukemia with t (8; 21) and myelomonocytic leukemia with inv (16) represent 30–40 % of AML with overall survival

70 %. Total treatment results are steadily improving with a chance to achieve remission over 90 % and overall survival over 60 %.

Keywords: acute lymphoblastic leukemia, acute myeloid leukemia, biology, treatment, children

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Starý J. Acute leukemias in children. Onkologie. 2010;4(2):120-124.
Download citation

References

  1. Hrušák O, Trka J, Zuna J, Poloučková A, Kalina T, Starý J. Acute lymphoblastic leukemia incidence during socioeconomic transition: selective increase in children from 1 to 4 years. Leukemia 2002; 16: 720-725. Go to original source... Go to PubMed...
  2. Trka J, Zuna J, Hrušák O, et al. Hybridní gen TEL/AML1 asociovaný s akutní leukemií vzniká v průběhu normálního fetálního vývoje a je detekovatelný v pupečníkové krvi zdravých novorozenců. Čs. Pediatrie 2003; 58: 471-477.
  3. Burjanivová T, Madžo J, Mužíková K, et al. Prenatal origin of childhood AML occurs less frequently than in childhood ALL. BMC Cancer. 2006; 6: 100. Go to original source... Go to PubMed...
  4. Greaves N. Infection, immune responses and the aetiology of childhood leukaemia. Nature Rev Cancer 2006; 6: 193-203. Go to original source... Go to PubMed...
  5. European group for the immunological characterisation of leukaemias (EGIL), Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukaemias. Leukemia 1995; 9: 1783-1786.
  6. Zuna J, Hrušák O, Kalinová M, et al. Significantly lower relapse rate for TEL/AML1-positive ALL. Leukemia 1999; 13: 1633-1638. Go to original source... Go to PubMed...
  7. Starý J, Vávra V, Zuna J, et al. Interfant 99-léčebná studie zohledňující odlišnou biologii akutní lymfoblastické leukemie kojenců a její výsledky v České republice. Transfuze Hematol dnes 2009; 15: 83-90.
  8. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 5175-5181. Go to original source... Go to PubMed...
  9. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transf 1990; 33: 439-450. Go to original source... Go to PubMed...
  10. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplantation for very-high risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005; 366: 635-642. Go to original source... Go to PubMed...
  11. Froňková E, Mejstříková E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL ICBFM 2002 protocol for childhood ALL: is it possible to avoid MRD testing? Leukemia. 2008; 22: 989-997. Go to original source... Go to PubMed...
  12. Mejstříková E, Froňková E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010; 54: 62-70. Go to original source... Go to PubMed...
  13. Starý J, Jabali Y, Trka J, et al. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 2010; 24: 425-428. Go to original source... Go to PubMed...
  14. Möricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24: 265-284. Go to original source... Go to PubMed...
  15. Boissel N, Auclerc MF, Lhéritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780. Go to original source... Go to PubMed...
  16. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric AML patiens treated uniformly according to trial AML-BFM 98. JCO 2010; v tisku. Go to original source...
  17. Balgobind B, Raimondi S, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114: 2489-2496. Go to original source... Go to PubMed...
  18. Starý J, Vávra V, Gajdoš P, et al. Druhá celostátní léčebná studie AML-BFM 98 zvýšila úspěšnost v dosažení remise a zlepšila celkové přežití dětí s akutní myeloidní leukemií v České republice. Transfuze Hemat dnes 2008; 14(4): 167-174.
  19. Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 2010; v tisku. Go to original source... Go to PubMed...
  20. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113: 2619-2628. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.